Shionogi to buy IntraBio for USD 2 billion

PUBT · 2d ago
Shionogi to buy IntraBio for USD 2 billion
  • Shionogi agreed to buy IntraBio for an upfront USD 2 billion, adding rare-disease drug AQNEURSA to its portfolio.
  • IntraBio would become a wholly owned unit of Shionogi’s U.S. subsidiary upon closing, targeted for November–December 2026.
  • AQNEURSA won U.S. approval in 2024 for neurological manifestations of Niemann-Pick disease type C.
  • The FDA cleared AQNEURSA on Sept. 18, 2026 for ataxia in Ataxia-Telangiectasia, making it the only approved treatment.
  • Deal adds global rights to AQNEURSA and broadens Shionogi’s rare-disease push following its April 2026 acquisition of RADICAVA rights.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shionogi & Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610050800BIZWIRE_USPR_____20261005_BW854293) on October 05, 2026, and is solely responsible for the information contained therein.